Physician profile
Young J Lee
NPI 1609068659
$2,177.74
in general payments reported to CMS, 2019-2025
25 companies · $33.57 in 2025
The $33.57 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $819 · 2020: $14.49 · 2022: $213 · 2023: $508 · 2024: $590 · 2025: $33.57.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,126 · Travel and Lodging: $5.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,125.83 |
| Travel and Lodging | $5.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $520.83 | 2019-2024 | Senza |
| Vertos Medical, INC. | $443.63 | 2019-2023 | Mild Device Kit |
| Grt US Holding, INC. | $213.00 | 2022 | |
| Si-Bone, INC. | $173.35 | 2019-2024 | |
| International Rehabilitative Sciences, INC | $147.32 | 2024 | Rs 4i Plus Sequential Stimulator |
| Painteq LLC | $132.27 | 2024 | Painteq |
| Abbott Laboratories | $90.00 | 2023 | Eterna |
| Medtronic, INC. | $89.81 | 2023 | Intellis Adaptivestim |
| Biodelivery Sciences International, INC. | $41.69 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.17 | 2019 | |
| Mml US, INC. | $33.61 | 2024 | Reactiv8 |
| Globus Medical, INC. | $33.57 | 2025 | Senza |
| Astrazeneca Pharmaceuticals LP | $26.69 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $25.15 | 2019 | |
| Spr Therapeutics, INC | $20.14 | 2024 | Sprint Pns System |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $19.50 | 2024 | |
| Alexion Pharmaceuticals, INC. | $18.73 | 2024 | Strensiq |
| Depuy Synthes Sales INC. | $16.78 | 2019 | |
| Acorda Therapeutics, INC | $14.69 | 2019 | |
| Mdd US Operations, LLC | $14.49 | 2020 | |
| Pfizer INC. | $14.45 | 2019 | |
| Pacira Therapeutics, INC. | $14.24 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.05 | 2019 | |
| Owp Pharmaceuticals, INC. | $12.86 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Young Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.